GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » EBITDA per Share

Cantel Medical (Cantel Medical) EBITDA per Share : $4.86 (TTM As of Apr. 2021)


View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical EBITDA per Share?

Cantel Medical's EBITDA per Share for the three months ended in Apr. 2021 was $1.48. Its EBITDA per Share for the trailing twelve months (TTM) ended in Apr. 2021 was $4.86.

During the past 12 months, the average EBITDA per Share Growth Rate of Cantel Medical was 56.30% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -5.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 1.90% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Cantel Medical's EBITDA per Share or its related term are showing as below:

CMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.4   Med: 16   Max: 148.6
Current: -5.7

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Cantel Medical was 148.60% per year. The lowest was -36.40% per year. And the median was 16.00% per year.

CMD's 3-Year EBITDA Growth Rate is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 9.65 vs CMD: -5.70

Cantel Medical's EBITDA for the three months ended in Apr. 2021 was $66 Mil.

During the past 12 months, the average EBITDA Growth Rate of Cantel Medical was 59.00% per year. During the past 3 years, the average EBITDA Growth Rate was -5.10% per year. During the past 5 years, the average EBITDA Growth Rate was 2.40% per year. During the past 10 years, the average EBITDA Growth Rate was 15.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Cantel Medical was 157.20% per year. The lowest was -27.40% per year. And the median was 17.70% per year.


Cantel Medical EBITDA per Share Historical Data

The historical data trend for Cantel Medical's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantel Medical EBITDA per Share Chart

Cantel Medical Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.96 3.47 3.79 3.05 2.90

Cantel Medical Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.56 1.65 1.18 1.48

Cantel Medical EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cantel Medical's EBITDA per Share for the fiscal year that ended in Jul. 2020 is calculated as

EBITDA per Share(A: Jul. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=122.651/42.309
=2.90

Cantel Medical's EBITDA per Share for the quarter that ended in Apr. 2021 is calculated as

EBITDA per Share(Q: Apr. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=66.258/44.932
=1.47

EBITDA per Share for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantel Medical  (NYSE:CMD) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Cantel Medical EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Cantel Medical's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantel Medical (Cantel Medical) Business Description

Traded in Other Exchanges
N/A
Address
150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424
Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.
Executives
Ann E Berman director 255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann officer: SVP, General Counsel 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades director, officer: Chief Executive Officer 281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker director, 10 percent owner, officer: Chairman ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman officer: SVP - CFO C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner officer: SVP and CHRO 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone officer: SVP and Princ. Accounting Ofr 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford officer: President and COO 40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin officer: Executive Vice President 150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese director 849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost director JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin director C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers director TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin director 399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316

Cantel Medical (Cantel Medical) Headlines

From GuruFocus

Cantel Hires Michael Drexel to SVP and Chief Technology Officer

By PRNewswire PRNewswire 10-01-2020

Cantel Pre-Announces Estimated Revenue for the 4th Quarter

By PRNewswire PRNewswire 08-06-2020